Evidence map›Paper›PMID 26413562›Full record

ArticleAlzheimer's & dementia (Amsterdam, Netherlands)2015

Oral glucose tolerance testing to modulate plasma amyloid levels: A novel biomarker.

Esther S Oh, Christopher M Marano, Jeannie-Marie Leoutsakos, Rebecca W Lee, Robert A Rissman, Gwenn S Smith, Suzanne Craft, Constantine G Lyketsos

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia (Amsterdam, Netherlands), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Esther S OhDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA ; Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD, USA ; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA ; Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Christopher M MaranoDepartment of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Jeannie-Marie LeoutsakosDepartment of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD, USA ; Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Rebecca W LeeDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Robert A RissmanAlzheimer's Disease Cooperative Study, Department of Neurosciences, University of California San Diego, School of Medicine, San Diego, CA, USA.
Gwenn S SmithDepartment of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Suzanne CraftDepartment of Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Constantine G LyketsosDepartment of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Funding

Institute for Clinical and Translational ResearchUL1TR001079 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2013 to 2017
$60.1M
'T V ASSESSMENT - MEMORY DISORDERED PATIENTS'P50AG005146 · NIA · JOHNS HOPKINS UNIVERSITY · PI LYKETSOS, CONSTANTINE G · 1985 to 2019
$37.6M
Institute for Clinical and Translational Research (KL2)KL2RR025006 · NCRR · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2007 to 2011
$12.9M
Geriatric Depression: PET Studies of Pathophysiology and Treatment ResponseR01MH086881 · NIMH · JOHNS HOPKINS UNIVERSITY · PI SMITH, GWENN S · 2010 to 2013
$2.7M
PET Studies of Serotonin and Amyloid in MCIR01AG038893 · NIA · JOHNS HOPKINS UNIVERSITY · PI SMITH, GWENN S · 2011 to 2014
$2.4M
Insulin Resistance in Late-Life DepressionK23MH095971 · NIMH · JOHNS HOPKINS UNIVERSITY · PI MARANO, CHRISTOPHER · 2012 to 2016
$903k
CSF predictors of postoperative delirium in non-demented hip fracture patientsK23AG043504 · NIA · JOHNS HOPKINS UNIVERSITY · PI OH, ESTHER SEUNGHEE · 2012 to 2016
$819k
Oral Glucose Tolerance Test for Alzheimer's Disease Biomarker DevelopmentR21AG033769 · NIA · JOHNS HOPKINS UNIVERSITY · PI CRAFT, SUZANNE, OH, ESTHER SEUNGHEE · 2010 to 2011
$368k
NCATS NIH HHS UL1 TR001079NCRR NIH HHS KL2 RR025006NIA NIH HHS K23 AG043504NIA NIH HHS P50 AG005146NIA NIH HHS R01 AG038893NIA NIH HHS R21 AG033769NIMH NIH HHS K23 MH095971NIMH NIH HHS R01 MH086881
6 · The paper itself

Abstract

introductionPlasma levels of amyloid-beta (Aβ) do not correlate well with different stages of Alzheimer's disease (AD) in cross-sectional studies. Measuring the changes in Aβ plasma levels with an acute intervention may be more sensitive to distinguishing individuals in earlier stages of AD (mild cognitive impairment; MCI) from normal controls.

methods57 participants (18 with AD/MCI and 39 cognitively normal controls) underwent oral glucose tolerance testing (OGTT). Blood samples were obtained over a 2 hour time period. Changes in plasma Aβ40 and42 levels were measured from either baseline or 5 minutes to the 10 minute time point.

resultsCompared to normal controls, subjects with AD/MCI had significantly less change (Δ) in plasma levels for both Aβ40(-3.13(40.93)pg/ml vs. 41.34(57.16)pg/ml;p=0.002) and Aβ42(-0.15(3.77)pg/ml vs. 5.64(10.65)pg/ml; p=0.004). DISCUSSION: OGTT combined with measures of plasma Aβ40 and 42 is potentially useful in distinguishing aging individuals who are in different stages of AD.

Indexed as

Alzheimer's diseaseblood biomarkeroral glucose tolerance test

Identifiers

PMID26413562
PMCPMC4578701

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.